Daniel T. Ginat to Cetuximab
This is a "connection" page, showing publications Daniel T. Ginat has written about Cetuximab.
Connection Strength
0.041
-
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019 02 01; 30(2):297-302.
Score: 0.041
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.